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most common isolates were yeast like fungi- 14 strains (99%). The
dominant strains from Candida genus were C. glabrata 4 (28.5%),
C. krusei 4 (28.5%), C. albicans 2 (14.3%), C. tropicalis 1 (7.2%),
C. parapsilosis 1 (7.2%). Other fungal strains: Cryptococcus neo-
formans isolated in 2 cases (14.3%) and Aspergillus fumigatus. 1
strain- 6.7% out of the total number of cultures. The susceptibil-
ity of isolates for Amphotericine B and Voriconazole was 100%. In
13 strains which were tested for Itraconazole, 6 (46%) were re-
sistant, the 16.7% of analyzed spesies were Flukonazole resistant.
100% of C. glabrata isolates were susceptible for Caspofungin and
Posaconazole.
Conclusions: The performed analyses indicated that yeast like
fungi had the highest contribution in fungemias (99%). The main
etiological factors of fungemia in immunodeficient patients were
non-albicans species 66.7% 3. The dominant species from Can-
dida genus with increased resistance for antifungal agents were
C. glabrata 33.3% and C.krusei 33.3%. The most efficient antifun-
gal agents were in vitro Amphotericin B and Voriconazole.
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A Case of Pulmonary Angioinvasive Zygomycosis in a
Patient with Acute Promyelocytic Leukemia successfully
treated with Surgical Resection and Posaconazole
Julio Mendez. Mayo Clinic Jacksonville, Division of Infectious
Diseases, Jacksonville, Florida, USA
31-year-old African American male patient previously healthy and
a retired professional football player presented to his primary care
physician on early August of 2007 complaining of cough, and ini-
tially treated for a suspected upper respiratory infection with cef-
podoxime and doxycycline without any improvement. On August
20, 2007, he developed hemoptysis and was found to have ane-
mia (8.2 g/dL), thrombocytopenia (23,000/mm3) and leukocytosis
(14.500/mm3) with 50% blasts. A bone marrow biopsy on August
21, 2007 was consistent with Acute Promyelocytic Leukemia (APL)
and started induction chemotherapy on August 24, 2007 with ATRA,
Idarubicin, and Dexamethasone until August 30, 2007 when Idaru-
bicin and Dexamethasone were discontinued and was kept on ATRA.
He became neutropenic on August 27, 2007 and on September 9,
2007 developed fever associated with a right middle lobe consoli-
dation and a right pleural effusion and thoracentesis cultures were
negative. He remained neutropenic until September 17, 2007 and
during this time received broad spectrum antibiotics and antifun-
gals including Caspofungin from August 24, 2007 to September 6,
2007, Voriconazole from September 6, to September 10, 2007 and
Ambisome from September 10, 2007 until October 9, 2007. On
September 21, 2007 and due to the progression of the infiltrate,
he had a bronchoscopy and a transbronchial biopsy was consis-
tent with Angioinvasive Zygomycosis and was kept on intravenous
Ambisome and Posaconazole was added. On October 1, 2007, he
underwent a right exploratory thoracotomy with decortication of
the right lower lobe and partial parietal pleurectomy and right
middle lobectomy and the pathologic report showed Angioinvasive
Zygomycosis, however, the fungal cultures were negative. He re-
mained on intravenous Ambisome and Posaconazole and fourteen
days later was dismissed home on Posaconazole with the intention
to continue this agent while on therapy for the APL and to extend
the treatment for one additional year post-remission. PCRs for APL
in peripheral blood have been negative since October 15, 2007.
Conclusion: He is currently on therapy for the APL with ATRA,
Methotrexate, and 6-Mercaptopurine and the plan is to extend
this regimen for two years. He was re-evaluated on February 5,
2008 and was asymptomatic and follow-up chest x-rays have con-
tinued to show signs of resolution and is now only consistent with
post-operative changes. He has continued to tolerate Posaconazole
well.
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Invasive Zygomycoses in a Tertiary Hhaematooncological
Centre in the Czech Republic
Michal Kouba1, Vít Campr2, David Pohlreich1, Petr Cetkovský1.
1Institute of Haematology and Blood Transfusion, Clinical
Department, Prague, Czech Republic; 2Institute of Pathology and
Molecular Medicine of the 2nd Medical Faculty of the Charles
University, University Hospital Motol, Prague, Czech Republic
Background: Infections by Zygomycetes (class Zygomycetes, most
infections by fungi of the Mucorales order) are rare emerging
mould infections found almost exclusively among immunocompro-
mised patients (malignant diseases, after haematopietic stem cell
transplantation (HSCT) or solid organ transplantation, neutrope-
nia, iron overload, diabetes mellitus, drug addiction ...). In the
last decades the number of referred cases in English written lit-
erature increased. The outcome of treatment is slowly improving
due to aggressive surgical treatment together with modern antimy-
cotic treatment. In spite of that the mortality of pulmonary form
remains over 80%.
Materials: We summarized the invasive infections by Zygomycetes
in a 33 bed (21 standard beds, 8 intensive care beds, 4 transplant
beds) tertiary hematooncological centre in Prague, Czech Republic.
Methods: A prospective monitoring of mould infections in the time
period 1/2003-12/2007 was used and we choose only the proven
cases (according to EORTC-MSG criteria).
Results: There were two clusters of infections by Zygomycetes in
60 months – 4 proven cases in 1-4/2003, all caused by Rhizomucor
pusillus, which had been identified in hospital environment be-
fore the clinical cases appeared. 2 proven cases 12/2005-1/2006
were identified by histology without further specification by cul-
ture. Four of 6 patients were after HSCT and 2 after therapy for
acute leukemias. Five of 6 patients developed pulmonary form,
one of HSCT patients developed disseminated form. 4 patients died
from the progression of mycosis, one died from the relapsing ma-
lignancy, one patient lives without any sign of fungal infection.
Conclusions: The aforementioned cases support the evidence of
poor outcome of zygomycoses in haematooncology patients. The
predominance of pulmonary form and high mortality in this patient
group is in concordance with literature. The clustering of cases
to two time periods and identification of Zygomycetes in hospital
environment prior to the first period support the idea of higher
vigilance and/or preventive measures (change in antimycotic pol-
icy or temporary closure of the unit) when these extremely dan-
gerous fungi are found in the environment of immunocompromised
patient.
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Immunocompromised Patients with Possible Sphenoid Sinus
Aspergilloma the Role of Detection of Aspergillus Antigen
Galactomannan
Polyzo Kazila1, Eleni Kaitsa1, Soultana Kostopoulou1,
Evaggelos Antonakis1, Vasiliki Gastari2, Eirini Katodritou2,
Konstantinos Zervas2. 1Laboratory of Microbiology, “Theagenio"
Cancer Hospital, Thessaloniki Greece; 2Haematology Clinic,
“Theagenio" Cancer Hospital, Thessaloniki Greece
Background: The invasive infections from Aspergillus are a major
cause of morbidity and mortality in immunocompromised patients.
The diagnosis is based on the histological tests and the growth of
the fungus in a tissue culture, after a dangerous and therefore
avoided in neutropenic patient' s biopsy. The combination of the
detection of Aspergillus antigen Galactomannan (GM) in serum and
X-ray findings is considered to be an indication equivalent to a pos-
itive biopsy sample.
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Objectives and Results: The aim of our study was to present a case
of a leukemic patient with possible sphenoid sinus aspergilloma and
to evaluate the diagnostic value of the detection of the GM anti-
gen. Case report: A patient with AML (M4/FAB) is hospitalized with
recurrence of the illness since September 2007. Since 15 November
2007, he has been presenting neutropenia. From the date of the
admission until 28 November 2007, 51 cultures of several biologic
materials were performed and 8 serum samples were examined
for detection of the GM antigen, using a double sandwich assay
ELISA (Sanofi Diagnostics Pasteur). All the laboratory tests found
negative for fungi. At 29 November 2007 the patient presented
paresis of the left abducens nerve and fever. At 30 November 2007
the serum sample for GM was positive (r=0.77, n.v<0.5) and the
brain-splachnic skull CT showed almost complete takeover of the
left sphenoid sinus from a solid mass. At 3 December 2007 GM was
detected in CSF (strongly positive, r=7.18), as well as in a new
serum sample (r=0.78).The CSF culture was negative, whereas the
cytologic test ruled out the possibility of infiltration with leukemic
cells. According to these findings and the possible diagnosis of as-
pergillosis, the patient was treated with liposomic amphotericin
and caspofungin. Three more serum samples followed, until 10 De-
cember 2007, which were found positive for GM with progressively
raising titre (r=2.61), whereas ups and downs of the titre were
observed in 4 samples until 19 December 2007 (r=1.26-2.75).The
detection of GM in CSF at 17 December 2007 was again strongly
positive. Aspergillus was not isolated in any of the 14 cultures that
were performed. The patient is being hospitalized under treat-
ment, afebrile, in good shape and with stable x-ray findings.
Conclusions: The detection of GM antigen, in as many serum sam-
ples as possible from high risk patients, seems to contribute to
early diagnosis and therapeutic management of aspergillosis.
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Influence of Central Venous Catheter Management on
Outcome in Cancer Patients with Candidemia who Survived
more than 72 Hours after the First Positive Blood Culture
Eduardo Velasco1, Rodrigo Doyle Portugal2. 1National Cancer
Institute, Hospital do Cancer, Rio de Janeiro, Brazil; 2University
Hospital, Hematology Service, Universidade Federal do Rio de
Janeiro, Brazil
Background: Removal of central venous catheter (CVC) from pa-
tients with candidemia is considered to be the standard of care.
Objective: To evaluate the epidemiology and the impact of early
versus delayed CVC removal on mortality of patients who survived
more than 72h after the first positive blood culture.
Patients and Methods: Between January 2001 and June 2005 a
prospective cohort study involving 192 hospitalized cancer patients
with CVC and candidemia was conducted at a tertiary cancer cen-
ter in Brazil. The study enrolled 164 patients who survived >3 days
and had their catheters removed during the study period. Patients
with CVC removal within 3 days of candidemia onset were classified
as having an early CVC removal. Overall mortality was evaluated
30 days after the index positive blood culture.
Results: Early CVC removal occurred in 61% of cases (100 of 164)
with a median removal time of 2 days (range 0-29 days). Patients
with early CVC removal differed significantly from those with de-
layed CVC removal, and they were more often female, had poor
performance status, other associated infected sites, short-duration
catheter type, and previous history of bacteremia, total parenteral
nutrition, and admission to intensive care unit. Multivariate anal-
ysis showed only the short-duration catheter type as significantly
associated with early removal. Overall mortality rate was 10.4% (17
of 164). CVC removal within 72h did not show a favorable impact
on mortality when compared with delayed removal (11% vs. 9.4%;
P=0.94). Multivariate analysis revealed that adults, lymphoma,
presence of comorbidities, use of steroid therapy, long-duration
neutropenia (>7 days) after the first positive blood culture, and
isolation of C. glabrata, C. krusei and C. tropicalis species from
blood cultures were independently associated with death.
Conclusion: Despite the significant difference in clinical charac-
teristics between patients with early and delayed CVC removal,
only short-duration catheter type was independently associated
with early removal. We were not able to demonstrate any ben-
eficial impact of early CVC removal on mortality among patients
who survived more than 72h after the index positive blood culture.
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Epidemiological Study of Trichosporonemia in Patients with
Hematological Diseases in Japan
Issei Tokimatsu1, Hisako Kushima1, Jun-ichi Kadota1,
Takashi Sugita2, Shunji Takakura3, Tohru Takata4,
Takahiro Fukuda5, Kazuo Tamura4. 1Department of Infectious
Diseases, Oita University Faculty of Medicine, Oita, Japan;
2Department of Microbiology, Meiji Pharmaceutical University,
Tokyo, Japan; 3Department of Infection Control & Prevention,
Kyoto University Hospital, Kyoto, Japan; 4Department of Internal
Medicine, Fukuoka University School of Medicine, Fukuoka,
Japan; 5Hematopoietic Stem Cell Transplantation Unit, National
Cancer Center Hospital, Tokyo, Japan
Background: Disseminated trichosporonosis, caused by species of
the fungus Trichosporon, develops in neutropenic patients and is
described as a breakthrough infection that may develop even dur-
ing the use of antifungal drugs. However, little is known about the
current epidemiology of this disease. We organized an epidemio-
logic study of trichosporonosis to clarify the background and actual
treatment of trichosporonemia in Japan.
Materials and Methods: We sent a questionnaire about dissemi-
nated trichosporonosis to 459 hospitals throughout Japan that have
a physician specializing in hematology. Case reports with clinical
information on past cases with blood culture yielding Trichosporon
species from January 2000 to January 2008 were returned to us.
The risk factors, presence/absence of breakthrough infection, out-
come and efficacy of antifungal regimens for trichosporonemia
were investigated using these case reports.
Results: We received 48 case reports of trichosporonemia from
28 institutions. The most common underlying disease was acute
myeloid leukemia, which accounted for 62.5% (30) of cases. Of the
48 cases, 79.2% had neutropenia (polymorphonuclear leukocytes
< 500/mm3). Prior to onset of infection, 87.5% (42 cases) had
received several antifungal agents. The most common antifungal
agent administered before onset of trichosporonemia was mica-
fungin (28 of 42 cases; 66.7%), while 21 cases were administered
this drug for more than two weeks. Although various treatment
regimens were used for trichosporonosis, the mortality rate within
30 days was 70.8% in this study. Only voriconazole was significantly
effective for survival over 30 days after detection of this fungi
in blood (survival rate; 66.7%), compared with regimens without
voriconazole (P<0.05).
Conclusions: Trichosporonosis is a life-threatening infection in
cases of hematological malignancy, and is sometimes observed
even during long-term administration of micafungin in Japan. Tri-
chosporon species do not show sensitivity to echinocandin anti-
fungal drugs, and thus trichosporonosis would develop as a break-
through infection with the use of micafungin. This clinical data in-
dicates that voriconazole is an effective agent for trichosporonosis
in patients with hematological disease.
